Senator Hatch, before pressuring Colombia over cancer drug compulsory license, wanted one for Napster
(More on Colombia here: /colombia)
Continue Reading
Access to Medicine
2016: Dedalus Pharma, LLC, KEI comments on NIH proposal for exclusive licenses on CARs to treat cancer
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On April 22nd, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Dedalus… Continue Reading
2016: KEI objections to NIH licenses to Vital Spark, Kalytera Therapeutics, CB1 receptor mediating compounds
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) May 4, 2016 Betty Tong, Ph.D. Senior Licensing and Patenting Manager Technology Advancement Office National Institute of Diabetes and Digestive and Kidney Diseases 12A South… Continue Reading
WHO releases program of work and progress report in advance of Consultative Expert Working Group on R&D (2-4 May 2016)
The World Health Organization (WHO) is convening an open-ended meeting of member states on the Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) in Geneva, Switzerland at WHO headquarters from 2 May 2016 to 4 May 2016. The WHO has published the provisional agenda, the proposed program of work and progress report. Continue Reading
2016: NIH licenses on Boron Neutron patents, to Beijing Lanyears Communication
2016: NIH license on patents on 5T4 Antibodies for cancer treatment, diagnostics, to Ovensa, located in Ontario, Canada
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) These are the April 17, 2016 KEI comments on the NIH proposed exclusive license to Ovensa, for patents on 5T4 antibodies for cancer treatment and… Continue Reading
CDIP 17: Asia Pacific and African Group raise concerns re: WIPO’s position on the UN High-Level Panel on Access to Medicines
The World Intellectual Property Organization (WIPO) is convening its 17th session of the Committee on Intellectual Property and Development (CDIP17) from 11 April 2016 to 15 April 2016. The mandate of the Committee is to “develop a work-program for implementing the 45 adopted Development Agenda recommendations” and “monitor, assess, discuss and report on the implementation of all recommendations adopted” (Source: WIPO page on the Committee on Development And Intellectual Property).
2016: Objection to exclusive license to AestasRx Inc.
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) Susan Ano, Ph.D., NINDS Technology Transfer, 31 Center Drive, Suite 8A52, MSC2540 Bethesda, MD 20892; Telephone: (301) 435-5515; anos@mail.nih.gov Dear Dr. Ano, I am writing to express… Continue Reading
2016: Midissia Therapeutics license of NIH owned breast and prostate cancer vaccine patents
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) Sabarni K. Chatterjee, Ph.D., M.B.A. Senior Licensing and Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702… Continue Reading
BIO, PhRMA and US Chamber of Commerce express fear of UN High-Level Panel on Access to Medicines in letter to Senator Hatch
In a sternly worded letter dated 18 February 2016, the Biotechnology Innovation Organization (BIO), the National Association of Manufacturers (NAM), the National Foreign Trade Council (NFTC), the Pharmaceutical Research and Manufacturers of America (PhRMA), the U.S. Chamber of Commerce (the Chamber) and the United States Council for International Business (USCIB) wrote Senator Orrin Hatch (Republican – Utah) expressing serious reservations with the United Nations High-Level Panel on Access to Medicines (UN HLP). Continue Reading